Case Digest (G.R. No. 104217)
Facts:
The case revolves around Parke, Davis & Company (Petitioner) and Doctor's Pharmaceuticals, Inc., along with Tiburcio S. Evalle, who served as the Director of Patents (Respondents), and is formally known as G.R. No. L-27004. The events leading up to this case began when the Supreme Court affirmed a decision on August 31, 1965, which had ordered Parke, Davis & Co. (the patent holder) to grant Doctor's Pharmaceuticals a license to manufacture, use, and sell products containing the chemical chloramphenicol in the Philippines. This decision was derived from an earlier ruling on November 15, 1963, during Inter Partes Case No. 181. The Director of Patents directed both parties to negotiate a licensing agreement, failing which he would impose terms himself.In the absence of an agreement post-ruling, on March 25, 1966, and subsequently amended on November 25, 1966, the Director of Patents issued a license with fixed royalty terms which mandated Doctor's Pharmaceuticals to pay an 8
Case Digest (G.R. No. 104217)
Facts:
- Background of the Case
- Parties Involved
- Petitioner: Parke, Davis & Company, a subsidiary of the U.S. firm Parke, Davis & Company of Michigan.
- Respondents:
- Doctor’s Pharmaceuticals, Inc., a local pharmaceutical company;
- Tiburcio S. Evalle, in his capacity as Director of Patents.
- Relevant Patent
- The patented chemical “chloramphenicol” under Letters Patent No. 50 was at issue.
- The dispute arose from a compulsory license application involving the manufacturing, use, and sale of products containing the patented chemical.
- Prior Proceedings and Licensing Agreement Requirements
- In G.R. No. L-22221 (decision dated August 31, 1965), the Court had affirmed the decision of the Director of Patents rendered on November 15, 1963.
- The prior decision ordered petitioner Parke, Davis & Company to grant a license to respondent Doctor’s Pharmaceuticals, Inc.
- The resolution imposed a requirement for the parties to submit a licensing agreement within 30 days or, failing that, allow the Director of Patents to fix the terms.
- Issuance of the License by the Director of Patents
- Due to the failure of the parties to submit an agreement, the Director of Patents acted under the authority of Section 36 of Republic Act 165 (Patent Law).
- On March 25, 1966, with an amendment on November 25, 1966, the Director issued a license that:
- Fixed the terms and conditions of the license immediately.
- Imposed a royalty rate of 8% of net sales on all licensed products containing “chloramphenicol.”
- The licensing resolution declared that the agreement should take effect immediately, as provided by the law and the rules governing patent decisions.
- Controversy over the Royalty Rate
- Petitioner’s Position
- Claimed that the 8% royalty rate fixed by the Director of Patents was grossly inadequate.
- Argued for an increase to a 15% rate, basing its argument on:
- Evidence from compulsory licenses in other jurisdictions such as Great Britain (15%) and Canada (12 1/2%).
- The prevailing rates for compulsory licensing on net sales.
- Respondent’s Position
- Cited a licensing agreement between Collett & Co. of Norway and Lexal Laboratories of the Philippines that provided for royalties of 5% and 7% on other pharmaceutical products, suggesting that a lower rate was appropriate under local conditions.
- Emphasized the competitive disadvantage of local drug companies in the Philippines compared to large foreign entities, which justified a more liberal treatment in trade relations.
- Contentions Regarding the Authority of the Director and the Effectiveness of the Resolution
- Petitioner contended that the Director of Patents did not have the authority to make the licensing resolution effective immediately.
- Respondents and the Solicitor General argued that the provisions of Sec. 4, Rule 44 of the Rules of Court allowed the immediate execution of decisions by administrative bodies, including the Patent Office.
- It was noted that immediate executory effect was necessary to avoid interminable litigation, thereby ensuring the enforceability of compulsory licensing agreements.
- Expiry of the Patent
- The letter patent for the process, issued on February 9, 1950, was set to expire after seventeen years.
- Therefore, the patent had already expired on February 9, 1967, an important fact in the overall dispute.
Issues:
- Authority and Discretion of the Director of Patents
- Whether the Director of Patents properly exercised his authority under Section 36 of Republic Act 165 by fixing the licensing terms and conditions due to the parties’ failure to submit an agreement.
- Whether the immediate effect of the licensing resolution was legally sound under the Rules of Court.
- Appropriateness of the Fixing of the Royalty Rate
- Whether the 8% royalty rate established by the Director was reasonable in light of:
- The compromise between the petitioner’s request (15%) and the royalty rates prevailing in other comparable international cases (e.g., Canada and Great Britain).
- The circumstances of the local pharmaceutical industry’s competitive position compared to large multinational drug companies.
- Whether the administrative finding on the royalty rate was supported by substantial evidence and devoid of any abuse of discretion.
- Impact on the Local Drug Industry and Public Health
- Whether the imposition of the 8% royalty rate would cause any adverse business losses to petitioner or affect the saleability and pricing of antibiotics, impacting the health of the consuming public.
Ruling:
- (Subscriber-Only)
Ratio:
- (Subscriber-Only)
Doctrine:
- (Subscriber-Only)